MNPR Monopar Therapeutics Inc.
$71.84▲ +1.84%
Healthcare
Other
After hours
$71.90▲ +0.08%
Oct 27, 4:08 PM ET
Volume 135.9K
Avg Volume (10D) 121.5K
Key Metrics & Fundamentals
Market Cap
$482.20M
P/E Ratio
–
Div Yield
0.00%
52W Range
50.07 - 124.82
% vs 50 MA
-23.44%
% vs 200 MA
-6.90%
RSI-14
33.9
MACD Histogram
+0.7400
Beta (1Y vs SPY)
1.20
Free Cash Flow
-$3.25M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.64M
COGS
–
Operating Exp
$6.64M
Operating Income
-$6.64M
EBIT
-$6.64M
Pretax Income
-$5.31M
Net Income
-$5.31M
EPS (Diluted)
-0.62
Price & Volume History
Loading chart…
Recent News
Monopar Therapeutics Insider Sold Shares Worth $659,387, According to a Recent SEC Filing
MT Newswires · Oct 5, 2026 5:46 PM ET
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
GlobeNewswire · Aug 19, 2026 8:00 AM ET
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · Aug 13, 2026 3:36 PM ET
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald
MT Newswires · Aug 13, 2026 2:27 PM ET
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral From Overweight, Adjusts PT to $119 From $109
MT Newswires · Aug 13, 2026 7:17 AM ET
Monopar Therapeutics' Q2 Net Loss Widens
MT Newswires · Aug 12, 2026 9:47 AM ET
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 12, 2026 9:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See MNPR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.